University of Minnesota Cancer Center Achieves ‘Comprehensive’ Status

Publication
Article
OncologyONCOLOGY Vol 12 No 11
Volume 12
Issue 11

The University of Minnesota Cancer Center has been designated a "comprehensive cancer center" by the National Cancer Institute. To quality for the title "comprehensive," a center must conduct basic and clinical research, as well as prevention, control, and population studies; exhibit a strong body of interactive research bridging these key areas; and have outreach, education, and information programs in place. Only 35 of the 58 NCI-designated cancer centers meet the requirements for the "comprehensive" designation.

The University of Minnesota Cancer Center has been designated a "comprehensive cancer center" by the National Cancer Institute. To quality for the title "comprehensive," a center must conduct basic and clinical research, as well as prevention, control, and population studies; exhibit a strong body of interactive research bridging these key areas; and have outreach, education, and information programs in place. Only 35 of the 58 NCI-designated cancer centers meet the requirements for the "comprehensive" designation.

"We’re extremely pleased that the National Cancer Institute and our national peers have recognized the breadth of our cancer research program as well as our efforts to serve the community," said John H. Kersey, MD, director of the University of Minnesota Cancer Center. The University of Minnesota Cancer Center is the only NCI-designated comprehensive cancer center in the state of Minnesota

Related Videos
Estelamari Rodriguez, MD, MPH, an expert on lung cancer
Christine Bestvina, MD, an expert on lung cancer
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.